Radiation Oncology/Drugs/Radioimmunotherapy

Radioimmunotherapy (RIT) uses an antibody labeled with a radionuclide to deliver cytotoxic radiation to a target cell In cancer therapy, an antibody with specificity for a tumor-associated antigen is used to deliver a lethal dose of radiation to the tumor cells The ability for the antibody to specifically bind to a tumor-associated antigen increases the dose delivered to the tumor cells while decreasing the dose to normal tissues By its nature, RIT requires a tumor cell to express an antigen that is unique to the neoplasm or is not accessible in normal cells Steven M et al. Nat Rev Cancer. 2015 Jun; 15(6): 347–360. Radioimmunotherapy of human tumours (PMID: 25998714)